|
|Section2= |Section3= }} Pyr1 (LIMINIB) is an organic compound composed of carbon, hydrogen, oxygen and nitrogen that inhibits the enzyme LIM kinase. It was recently discovered by the Cure and Inserm Institute, CNRS and CEA, in collaboration with British and Australian investigators. The studies ''in vitro'' and with animals, published in ''Cancer Research'', prove that this molecule has a completely new mechanism of action that could be used against chemotherapy resistant cells, providing a new alternative treatment to cancer that does not have major side effects. Pyr1 reversibly stabilizes microtubules, blocks actin microfilament dynamics and inhibits cell motility ''in vitro''. These characteristics confer not only anticancer properties but also the capacity to prevent metastasis to the molecule. ==Description and properties== Pyr1 is classified as a small molecule that belongs to the group of pyridocarbazoles.〔(Pyridocarbazoles )〕 Its small size gives it special properties: as a light molecule it is a valuable tool for studying dynamic biological processes. Therefore, it is a key discovery in medical and biological investigation. It is a high degree protein temporal controller, as it is able to interact in a few minutes or even seconds with molecules such as LIMK1. Its reversibility enables it to quickly activate and inhibit itself, making the molecule a specific inhibitor both ''in vitro'' and ''in cellulo''. Pyr1 can be described as a tetracyclic molecule with a simple structure. Its few radicals are widely expanded along the benzene rings, distinguishing a benzoyloxy group in the ninth carbon and two methyl radicals in carbon five and eleven. There is also a ketone group in carbon one and two hydrogen radicals in carbons two and six. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Pyr1」の詳細全文を読む スポンサード リンク
|